Procter & Gamble Health Ltd
Procter & Gamble Health Q2 FY24: Revenue ₹1230 Cr, PAT ₹229 Cr
Q2 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on Procter & Gamble Health Ltd's Q2 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Reported revenue: ₹1230 crore (page 17) - Reported Profit After Tax (PAT): ₹229 crore (page 17) - Volume figure: 1.6 lakh units deployed across India (page 13) - No explicit year-on-year change figures or percentage growth provided in the presentation. The presentation does not provide explicit EBITDA or operating margin figures for the quarter, nor year-on-year changes for these metrics.
From Procter & Gamble Health Ltd's Q2 FY24 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Reported revenue: ₹1230 crore (page 17)
- Reported Profit After Tax (PAT): ₹229 crore (page 17)
- Volume figure: 1.6 lakh units deployed across India (page 13)
- No explicit year-on-year change figures or percentage growth provided in the presentation.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹370 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Procter & Gamble Health Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY24)
Revenue**: ₹6,435 crore, up 19% year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY24 earnings call — and how it ranks against sector…
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q2 FY24 results?
Reported revenue: ₹1230 crore (page 17) - Reported Profit After Tax (PAT): ₹229 crore (page 17) - Volume figure: 1.6 lakh units deployed across India (page 13) - No explicit year-on-year change figures or percentage growth provided in the presentation. The presentation does not provide explicit EBITDA or operating margin figures for the quarter, nor year-on-year changes for these metrics.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.
Is Procter & Gamble Health Ltd planning capital expenditure?
The presentation does not mention any details regarding capex, capacity expansion, new plants, or projects, including amounts, status, or timelines.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.